An Overview to Myelofibrosis and Disease Risk
Panelists discuss myelofibrosis (MF) and its diagnostic workup, including how patients with primary MF present, the criteria required for diagnosis, and any additional biomarkers or criteria examined in practice.
Read More
Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
Panelists discuss noteworthy updates in polycythemia vera (PV) from ASH 2024, explore the future of PV treatment, highlight the greatest unmet needs, and discuss how ongoing investigational therapies aim to address these gaps. They also share clinical pearls for community oncologists in managing PV.
Read More
Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.
Read More
Interferon Real- World Treatment Patterns in PV
Panelists discuss real-world treatment patterns for ropeginterferon alfa-2b (Ropeg alfa-2b) in the management of polycythemia vera (PV).
Read More
Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).
Read More
Safety Considerations for PV Therapy
Panelists discuss the safety profiles of therapies for polycythemia vera (PV) and the safety considerations they take into account when determining which patients are best suited for these treatments.
Read More
Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.
Read More
JAK Inhibition in Polycythemia Vera: Treatment Updates
Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.
Read More
Cytoreductive Therapy in PV Treatment Paradigm
Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.
Read More
Initial Treatment Strategies for Polycythemia Vera
Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.
Read More